相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy
Steven Coutre et al.
BLOOD (2018)
Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study
Inhye E. Ahn et al.
BLOOD (2018)
The rise of apoptosis: targeting apoptosis in hematologic malignancies
Rebecca Valentin et al.
BLOOD (2018)
Single-agent ibrutinib in treatment-naive and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience
Susan O'Brien et al.
BLOOD (2018)
Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in he United States
Anthony R. Mato et al.
HAEMATOLOGICA (2018)
Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study
Antonio Cuneo et al.
HAEMATOLOGICA (2018)
Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis
Anthony R. Mato et al.
HAEMATOLOGICA (2018)
Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in he United States
Anthony R. Mato et al.
HAEMATOLOGICA (2018)
Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study
Antonio Cuneo et al.
HAEMATOLOGICA (2018)
Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis
Anthony R. Mato et al.
HAEMATOLOGICA (2018)
Phase 2 CAPTIVATE results of ibrutinib (ibr) plus venetoclax (ven) in first-line chronic lymphocytic leukemia (CLL).
William G. Wierda et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
A phase 2 study to assess the safety and efficacy of umbralisib (TGR-1202) in pts with CLL who are intolerant to prior BTK or PI3K delta inhibitor therapy.
Anthony R. Mato et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
High, durable minimal residual disease negativity (MRD-) with venetoclax plus rituximab (VenR) in relapsed/refractory (R/R) CLL: MRD kinetics from phase 3 MURANO study.
Peter Hillmen et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia
Kerry A. Rogers et al.
BLOOD (2018)
Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax
Joan Montero et al.
CANCER DISCOVERY (2017)
Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study
John F. Seymour et al.
LANCET ONCOLOGY (2017)
Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax
Mary Ann Anderson et al.
BLOOD (2017)
Venetoclax and obinutuzumab in chronic lymphocytic leukemia
Kirsten Fischer et al.
BLOOD (2017)
Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience
Anthony R. Mato et al.
BLOOD (2016)
Ibrutinib for relapsed/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patients
HAEMATOLOGICA (2016)
Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study
Stephan Stilgenbauer et al.
LANCET ONCOLOGY (2016)
Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study
Asher Chanan-Khan et al.
LANCET ONCOLOGY (2016)
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
Andrew W. Roberts et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
John C. Byrd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Ibrutinib for relapsed/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patients
HAEMATOLOGICA (2016)
Complex Karyotype is a Stronger Predictor Than Del(17p) for an Inferior Outcome in Relapsed or Refractory Chronic Lymphocytic Leukemia Patients Treated With Ibrutinib-Based Regimens
Philip A. Thompson et al.
CANCER (2015)
Drug-Induced Death Signaling Strategy Rapidly Predicts Cancer Response to Chemotherapy
Joan Montero et al.
CELL (2015)
Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial
Mohammed Z. H. Farooqui et al.
LANCET ONCOLOGY (2015)
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
J. A. Burger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial
Susan O'Brien et al.
LANCET ONCOLOGY (2014)
Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study
Jan A. Burger et al.
LANCET ONCOLOGY (2014)
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
J. C. Byrd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
Richard R. Furman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
John C. Byrd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Neutrophil development and function critically depend on Bruton tyrosine kinase in a mouse model of X-linked agammaglobulinemia
Katja Fiedler et al.
BLOOD (2011)
Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members
Michael Certo et al.
CANCER CELL (2006)
Pleiotropic consequences of Bruton tyrosine kinase deficiency in myeloid lineages lead to poor inflammatory responses
A Mangla et al.
BLOOD (2004)
分享论文
